2024-09-012025-08-312025-08-31false06338124EPI-CURE CONSULTING LIMITED2026-04-27falseiso4217:GBPxbrli:pure063381242024-08-31063381242025-08-31063381242024-09-012025-08-31063381242023-08-31063381242024-08-31063381242023-09-012024-08-3106338124bus:SmallEntities2024-09-012025-08-3106338124bus:AuditExempt-NoAccountantsReport2024-09-012025-08-3106338124bus:FullAccounts2024-09-012025-08-3106338124bus:PrivateLimitedCompanyLtd2024-09-012025-08-3106338124core:WithinOneYear2025-08-3106338124core:AfterOneYear2025-08-3106338124core:WithinOneYear2024-08-3106338124core:AfterOneYear2024-08-3106338124core:ShareCapital2025-08-3106338124core:SharePremium2025-08-3106338124core:RevaluationReserve2025-08-3106338124core:OtherReservesSubtotal2025-08-3106338124core:RetainedEarningsAccumulatedLosses2025-08-3106338124core:ShareCapital2024-08-3106338124core:SharePremium2024-08-3106338124core:RevaluationReserve2024-08-3106338124core:OtherReservesSubtotal2024-08-3106338124core:RetainedEarningsAccumulatedLosses2024-08-3106338124core:LandBuildings2025-08-3106338124core:PlantMachinery2025-08-3106338124core:Vehicles2025-08-3106338124core:FurnitureFittings2025-08-3106338124core:OfficeEquipment2025-08-3106338124core:NetGoodwill2025-08-3106338124core:IntangibleAssetsOtherThanGoodwill2025-08-3106338124core:ListedExchangeTraded2025-08-3106338124core:UnlistedNon-exchangeTraded2025-08-3106338124core:LandBuildings2024-08-3106338124core:PlantMachinery2024-08-3106338124core:Vehicles2024-08-3106338124core:FurnitureFittings2024-08-3106338124core:OfficeEquipment2024-08-3106338124core:NetGoodwill2024-08-3106338124core:IntangibleAssetsOtherThanGoodwill2024-08-3106338124core:ListedExchangeTraded2024-08-3106338124core:UnlistedNon-exchangeTraded2024-08-3106338124core:LandBuildings2024-09-012025-08-3106338124core:PlantMachinery2024-09-012025-08-3106338124core:Vehicles2024-09-012025-08-3106338124core:FurnitureFittings2024-09-012025-08-3106338124core:OfficeEquipment2024-09-012025-08-3106338124core:NetGoodwill2024-09-012025-08-3106338124core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3106338124core:ListedExchangeTraded2024-09-012025-08-3106338124core:UnlistedNon-exchangeTraded2024-09-012025-08-3106338124core:MoreThanFiveYears2024-09-012025-08-3106338124core:Non-currentFinancialInstruments2025-08-3106338124core:Non-currentFinancialInstruments2024-08-3106338124dpl:CostSales2024-09-012025-08-3106338124dpl:DistributionCosts2024-09-012025-08-3106338124core:LandBuildings2024-09-012025-08-3106338124core:PlantMachinery2024-09-012025-08-3106338124core:Vehicles2024-09-012025-08-3106338124core:FurnitureFittings2024-09-012025-08-3106338124core:OfficeEquipment2024-09-012025-08-3106338124dpl:AdministrativeExpenses2024-09-012025-08-3106338124core:NetGoodwill2024-09-012025-08-3106338124core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3106338124dpl:GroupUndertakings2024-09-012025-08-3106338124dpl:ParticipatingInterests2024-09-012025-08-3106338124dpl:GroupUndertakingscore:ListedExchangeTraded2024-09-012025-08-3106338124core:ListedExchangeTraded2024-09-012025-08-3106338124dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-09-012025-08-3106338124core:UnlistedNon-exchangeTraded2024-09-012025-08-3106338124dpl:CostSales2023-09-012024-08-3106338124dpl:DistributionCosts2023-09-012024-08-3106338124core:LandBuildings2023-09-012024-08-3106338124core:PlantMachinery2023-09-012024-08-3106338124core:Vehicles2023-09-012024-08-3106338124core:FurnitureFittings2023-09-012024-08-3106338124core:OfficeEquipment2023-09-012024-08-3106338124dpl:AdministrativeExpenses2023-09-012024-08-3106338124core:NetGoodwill2023-09-012024-08-3106338124core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3106338124dpl:GroupUndertakings2023-09-012024-08-3106338124dpl:ParticipatingInterests2023-09-012024-08-3106338124dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3106338124core:ListedExchangeTraded2023-09-012024-08-3106338124dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3106338124core:UnlistedNon-exchangeTraded2023-09-012024-08-3106338124core:NetGoodwill2025-08-3106338124core:IntangibleAssetsOtherThanGoodwill2025-08-3106338124core:LandBuildings2025-08-3106338124core:PlantMachinery2025-08-3106338124core:Vehicles2025-08-3106338124core:FurnitureFittings2025-08-3106338124core:OfficeEquipment2025-08-3106338124core:AfterOneYear2025-08-3106338124core:WithinOneYear2025-08-3106338124core:ListedExchangeTraded2025-08-3106338124core:UnlistedNon-exchangeTraded2025-08-3106338124core:ShareCapital2025-08-3106338124core:SharePremium2025-08-3106338124core:RevaluationReserve2025-08-3106338124core:OtherReservesSubtotal2025-08-3106338124core:RetainedEarningsAccumulatedLosses2025-08-3106338124core:NetGoodwill2024-08-3106338124core:IntangibleAssetsOtherThanGoodwill2024-08-3106338124core:LandBuildings2024-08-3106338124core:PlantMachinery2024-08-3106338124core:Vehicles2024-08-3106338124core:FurnitureFittings2024-08-3106338124core:OfficeEquipment2024-08-3106338124core:AfterOneYear2024-08-3106338124core:WithinOneYear2024-08-3106338124core:ListedExchangeTraded2024-08-3106338124core:UnlistedNon-exchangeTraded2024-08-3106338124core:ShareCapital2024-08-3106338124core:SharePremium2024-08-3106338124core:RevaluationReserve2024-08-3106338124core:OtherReservesSubtotal2024-08-3106338124core:RetainedEarningsAccumulatedLosses2024-08-3106338124core:NetGoodwill2023-08-3106338124core:IntangibleAssetsOtherThanGoodwill2023-08-3106338124core:LandBuildings2023-08-3106338124core:PlantMachinery2023-08-3106338124core:Vehicles2023-08-3106338124core:FurnitureFittings2023-08-3106338124core:OfficeEquipment2023-08-3106338124core:AfterOneYear2023-08-3106338124core:WithinOneYear2023-08-3106338124core:ListedExchangeTraded2023-08-3106338124core:UnlistedNon-exchangeTraded2023-08-3106338124core:ShareCapital2023-08-3106338124core:SharePremium2023-08-3106338124core:RevaluationReserve2023-08-3106338124core:OtherReservesSubtotal2023-08-3106338124core:RetainedEarningsAccumulatedLosses2023-08-3106338124core:AfterOneYear2024-09-012025-08-3106338124core:WithinOneYear2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:CostValuation2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3106338124core:Non-currentFinancialInstrumentscore:CostValuation2025-08-3106338124core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-08-3106338124core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3106338124core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3106338124core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3106338124bus:Director12024-09-012025-08-3106338124core:FurnitureFittingsToolsEquipment2024-08-3106338124core:FurnitureFittingsToolsEquipment2025-08-3106338124core:FurnitureFittingsToolsEquipment2024-09-012025-08-31

EPI-CURE CONSULTING LIMITED

Registered Number
06338124
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2025

EPI-CURE CONSULTING LIMITED
Company Information
for the year from 1 September 2024 to 31 August 2025

Director

HOWE, Jeannette Ann

Registered Address

Linen Hall 162-168 Regent Street Room 252-254
London
W1B 5TB

Registered Number

06338124 (England and Wales)
EPI-CURE CONSULTING LIMITED
Balance Sheet as at
31 August 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets4245491
245491
Current assets
Debtors5144144
Cash at bank and on hand23,82157,882
23,96558,026
Creditors amounts falling due within one year6(4,315)(3,420)
Net current assets (liabilities)19,65054,606
Total assets less current liabilities19,89555,097
Net assets19,89555,097
Capital and reserves
Called up share capital11
Profit and loss account19,89455,096
Shareholders' funds19,89555,097
The financial statements were approved and authorised for issue by the Director on 27 April 2026, and are signed on its behalf by:
HOWE, Jeannette Ann
Director
Registered Company No. 06338124
EPI-CURE CONSULTING LIMITED
Notes to the Financial Statements
for the year ended 31 August 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Interest income
Interest income is recognised using the effective interest rate method.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Defined contribution pension plan
The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Plant and machinery3
Fixtures and fittings4
Office Equipment3
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20252024
Average number of employees during the year00
3.Deferred tax
Increases in the UK Corporation tax rate from 19% to 25% (19% effective from 1 April 2017, and 25% effective from 1 April 2023) have been substantively enacted. This will impact the company's future tax charge accordingly. The value of the deferred tax assets at the balance sheet date has been calculated using the applicable rate when the asset is expected to be realised.
4.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 September 241,2563,4076,65811,321
At 31 August 251,2563,4076,65811,321
Depreciation and impairment
At 01 September 241,2563,4076,16710,830
Charge for year--246246
At 31 August 251,2563,4076,41311,076
Net book value
At 31 August 25--245245
At 31 August 24--491491
5.Debtors: amounts due within one year

2025

2024

££
Other debtors144144
Total144144
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables245491
Amounts owed to related parties22-
Taxation and social security2,3561,249
Accrued liabilities and deferred income1,6921,680
Total4,3153,420
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.